These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 19099106)

  • 1. Gynecomastia: a rare adverse effect of isoniazid.
    Morrone N; Morrone Junior N; Braz AG; Maia JA
    J Bras Pneumol; 2008 Nov; 34(11):978-81. PubMed ID: 19099106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unilateral and painless development of isoniazid induced gynecomastia during re-treatment of pulmonary tuberculosis.
    Kumar L; Gupta R; Puri MM; Jaiswal A; Srinath ; Murar A; Behera D
    J Assoc Physicians India; 2011 Nov; 59():733-5. PubMed ID: 22616343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Isoniazid induced gynaecomastia: a case report.
    Garg R; Vaibhav ; Mehra S; Prasad R
    Indian J Tuberc; 2009 Jan; 56(1):51-4. PubMed ID: 19402273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isoniazid associated, painful, bilateral gynaecomastia.
    Khanna P; Panjabi C; Maurya V; Shah A
    Indian J Chest Dis Allied Sci; 2003; 45(4):277-9. PubMed ID: 12962465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Supervised six-months treatment of newly diagnosed pulmonary tuberculosis using isoniazid, rifampin, and pyrazinamide with and without streptomycin.
    Snider DE; Graczyk J; Bek E; Rogowski J
    Am Rev Respir Dis; 1984 Dec; 130(6):1091-4. PubMed ID: 6508006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A rare case of unilateral gynecomastia during antituberculous chemotherapy with isoniazid.
    Goud BK; Devi OS; Nayal B; Devaki RN
    Indian J Pharmacol; 2012; 44(4):521-2. PubMed ID: 23087519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A 32-year-old man with tuberculosis, fever, and rash.
    Story RE; Ditto AM
    Ann Allergy Asthma Immunol; 2004 May; 92(5):495-9. PubMed ID: 15191016
    [No Abstract]   [Full Text] [Related]  

  • 8. Safety of rifampin and pyrazinamide for the treatment of latent tuberculosis infection.
    Stout JE
    Expert Opin Drug Saf; 2004 May; 3(3):187-98. PubMed ID: 15155147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pyrazinamide and rifampin vs isoniazid for the treatment of latent tuberculosis: improved completion rates but more hepatotoxicity.
    McNeill L; Allen M; Estrada C; Cook P
    Chest; 2003 Jan; 123(1):102-6. PubMed ID: 12527609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of isoniazid-resistant tuberculosis with isoniazid, rifampin, ethambutol, and pyrazinamide for 6 months.
    Nolan CM; Goldberg SV
    Int J Tuberc Lung Dis; 2002 Nov; 6(11):952-8. PubMed ID: 12475140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pulmonary tuberculosis treated with isoprodian and rifampicin or pyrazinamide.
    Kleeberg HH
    Chemotherapy; 1987; 33(3):219-28. PubMed ID: 3297528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Weekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contacts.
    Schechter M; Zajdenverg R; Falco G; Barnes GL; Faulhaber JC; Coberly JS; Moore RD; Chaisson RE
    Am J Respir Crit Care Med; 2006 Apr; 173(8):922-6. PubMed ID: 16474028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Short-term therapy of lung tuberculosis using a fixed combination of isoniazid, rifampicin and pyrazinamide. Results after 2 years].
    Brändli O; Haegi V; Villiger B; Bohn W; Baumann HR; Zäch R
    Schweiz Med Wochenschr; 1989 Mar; 119(10):299-305. PubMed ID: 2652281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The effectiveness of pyrazinamide-containing six-month short course chemotherapy].
    Wada M
    Kekkaku; 2000 Nov; 75(11):665-73. PubMed ID: 11140090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month, three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin, and pyrazinamide. Results at 30 months. Hong Kong Chest Service/British Medical Research Council.
    Am Rev Respir Dis; 1991 Apr; 143(4 Pt 1):700-6. PubMed ID: 1901199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of adverse drug reaction and predictivity of quality of life status in tuberculosis.
    Guo N; Marra F; Fitzgerald JM; Elwood RK; Marra CA
    Eur Respir J; 2010 Jul; 36(1):206-8. PubMed ID: 20595167
    [No Abstract]   [Full Text] [Related]  

  • 17. Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society.
    Monaldi Arch Chest Dis; 1994 Sep; 49(4):327-45. PubMed ID: 8000420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Controlled clinical trial of five short-course (4-month) chemotherapy regimens in pulmonary tuberculosis. Second report of the 4th study. East African/British Medical Research Councils Study.
    Am Rev Respir Dis; 1981 Feb; 123(2):165-70. PubMed ID: 7015933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two-month regimen of isoniazid, rifampin and pirazinamid for latent tuberculosis infection.
    Duarte R; Carvalho A; Correia A
    Public Health; 2012 Sep; 126(9):760-2. PubMed ID: 22633080
    [No Abstract]   [Full Text] [Related]  

  • 20. [Fulminant hepatitis in the course of antitubercular treatment (apropos of 2 cases)].
    Mbaye PS; Talarmin F; Sane M; Eladari D; Klotz F
    Dakar Med; 1995; 40(2):129-31. PubMed ID: 9827070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.